{"pmid":32407757,"title":"Age but not sex may explain the negative effect of arterial hypertension and diabetes on COVID-19 prognosis.","text":["Age but not sex may explain the negative effect of arterial hypertension and diabetes on COVID-19 prognosis.","J Infect","Pirola, Carlos J","Sookoian, Silvia","32407757"],"journal":"J Infect","authors":["Pirola, Carlos J","Sookoian, Silvia"],"date":"2020-05-15T11:00:00Z","year":2020,"_id":"32407757","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.jinf.2020.05.010","keywords":["covid-19","cardiovascular disease","diabetes","hypertension","prognosis"],"topics":["Diagnosis","Treatment"],"weight":1,"_version_":1666802845308944384,"score":9.490897,"similar":[{"pmid":32474043,"title":"Estimation of RAAS-Inhibitor effect on the COVID-19 outcome: A Meta-analysis.","text":["Estimation of RAAS-Inhibitor effect on the COVID-19 outcome: A Meta-analysis.","BACKGROUND AND RATIONALE: Some studies of hospitalized patients suggested that the risk of death and/or severe illness due to COVID-19 is not associated with the use of angiotensin-converting enzyme inhibitors (ACEIs) and/or angiotensin II receptor type 1 blockers (ARBs). Nevertheless, some controversy still exists and there is limited information of the ACEIs/ARBs effect size on COVID-19 prognosis. AIM AND METHODS: We aimed to measure the effect of ACEIs and/or ARBs on COVID-19 severe clinical illness by a meta-analysis. Literature search included all studies published since the COVID-19 outbreak began (December 2019) until May 9, 2020. We analyzed information from studies that included tested COVID-19 patients with arterial hypertension as comorbidity prior to hospital admission and history of taking ACEIs, ARBs, or ACEIs/ARBs. RESULTS: We included 16 studies that involved 24,676 COVID-19 patients, and we compared patients with critical (n=4134) vs. non-critical (n=20,542) outcomes. The overall assessment by estimating random effects shows that the use of ACEIs/ARBs is not associated with higher risk of in-hospital-death and/or severe illness among hypertensive patients with COVID-19 infection. On the contrary, effect estimate shows an overall protective effect of RAAS inhibitors/blockers (ACEIs, ARBs, and/or ACEIs/ARBs) with approximately 23 % reduced risk f death and/or critical disease (OR: 0.768, 95%CI: 0.651-0.907, p=0.0018). The use of ACEIs (OR:0.652, 95%CI:0.478-0.891, p=0.0072) but not ACEIs/ARBs (OR:0.867, 95%CI:0.638-1.179, p =NS) or ARBs alone (OR:0.810, 95%CI:0.629-1.044, p=NS) may explain the overall protection displayed by RAAS intervention combined. CONCLUSION: RAAS inhibitors might be associated with better COVID-19 prognosis.","J Infect","Pirola, Carlos J","Sookoian, Silvia","32474043"],"abstract":["BACKGROUND AND RATIONALE: Some studies of hospitalized patients suggested that the risk of death and/or severe illness due to COVID-19 is not associated with the use of angiotensin-converting enzyme inhibitors (ACEIs) and/or angiotensin II receptor type 1 blockers (ARBs). Nevertheless, some controversy still exists and there is limited information of the ACEIs/ARBs effect size on COVID-19 prognosis. AIM AND METHODS: We aimed to measure the effect of ACEIs and/or ARBs on COVID-19 severe clinical illness by a meta-analysis. Literature search included all studies published since the COVID-19 outbreak began (December 2019) until May 9, 2020. We analyzed information from studies that included tested COVID-19 patients with arterial hypertension as comorbidity prior to hospital admission and history of taking ACEIs, ARBs, or ACEIs/ARBs. RESULTS: We included 16 studies that involved 24,676 COVID-19 patients, and we compared patients with critical (n=4134) vs. non-critical (n=20,542) outcomes. The overall assessment by estimating random effects shows that the use of ACEIs/ARBs is not associated with higher risk of in-hospital-death and/or severe illness among hypertensive patients with COVID-19 infection. On the contrary, effect estimate shows an overall protective effect of RAAS inhibitors/blockers (ACEIs, ARBs, and/or ACEIs/ARBs) with approximately 23 % reduced risk f death and/or critical disease (OR: 0.768, 95%CI: 0.651-0.907, p=0.0018). The use of ACEIs (OR:0.652, 95%CI:0.478-0.891, p=0.0072) but not ACEIs/ARBs (OR:0.867, 95%CI:0.638-1.179, p =NS) or ARBs alone (OR:0.810, 95%CI:0.629-1.044, p=NS) may explain the overall protection displayed by RAAS intervention combined. CONCLUSION: RAAS inhibitors might be associated with better COVID-19 prognosis."],"journal":"J Infect","authors":["Pirola, Carlos J","Sookoian, Silvia"],"date":"2020-06-01T11:00:00Z","year":2020,"_id":"32474043","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1016/j.jinf.2020.05.052","keywords":["angiotensin ii receptor type 1 blockers","angiotensin ii-converting enzyme inhibitors","covid-19","raas inhibitors","cardiovascular disease","diabetes","hypertension","prognosis"],"topics":["Treatment"],"weight":1,"_version_":1668341932713050112,"score":112.709175},{"pmid":32472191,"title":"Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study.","text":["Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study.","AIMS/HYPOTHESIS: Coronavirus disease-2019 (COVID-19) is a life-threatening infection caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) virus. Diabetes has rapidly emerged as a major comorbidity for COVID-19 severity. However, the phenotypic characteristics of diabetes in COVID-19 patients are unknown. METHODS: We conducted a nationwide multicentre observational study in people with diabetes hospitalised for COVID-19 in 53 French centres in the period 10-31 March 2020. The primary outcome combined tracheal intubation for mechanical ventilation and/or death within 7 days of admission. Age- and sex-adjusted multivariable logistic regressions were performed to assess the prognostic value of clinical and biological features with the endpoint. ORs are reported for a 1 SD increase after standardisation. RESULTS: The current analysis focused on 1317 participants: 64.9% men, mean age 69.8 +/- 13.0 years, median BMI 28.4 (25th-75th percentile: 25.0-32.7) kg/m(2); with a predominance of type 2 diabetes (88.5%). Microvascular and macrovascular diabetic complications were found in 46.8% and 40.8% of cases, respectively. The primary outcome was encountered in 29.0% (95% CI 26.6, 31.5) of participants, while 10.6% (9.0, 12.4) died and 18.0% (16.0, 20.2) were discharged on day 7. In univariate analysis, characteristics prior to admission significantly associated with the primary outcome were sex, BMI and previous treatment with renin-angiotensin-aldosterone system (RAAS) blockers, but not age, type of diabetes, HbA1c, diabetic complications or glucose-lowering therapies. In multivariable analyses with covariates prior to admission, only BMI remained positively associated with the primary outcome (OR 1.28 [1.10, 1.47]). On admission, dyspnoea (OR 2.10 [1.31, 3.35]), as well as lymphocyte count (OR 0.67 [0.50, 0.88]), C-reactive protein (OR 1.93 [1.43, 2.59]) and AST (OR 2.23 [1.70, 2.93]) levels were independent predictors of the primary outcome. Finally, age (OR 2.48 [1.74, 3.53]), treated obstructive sleep apnoea (OR 2.80 [1.46, 5.38]), and microvascular (OR 2.14 [1.16, 3.94]) and macrovascular complications (OR 2.54 [1.44, 4.50]) were independently associated with the risk of death on day 7. CONCLUSIONS/INTERPRETATIONS: In people with diabetes hospitalised for COVID-19, BMI, but not long-term glucose control, was positively and independently associated with tracheal intubation and/or death within 7 days. TRIAL REGISTRATION: clinicaltrials.gov NCT04324736.","Diabetologia","Cariou, Bertrand","Hadjadj, Samy","Wargny, Matthieu","Pichelin, Matthieu","Al-Salameh, Abdallah","Allix, Ingrid","Amadou, Coralie","Arnault, Gwenaelle","Baudoux, Florence","Bauduceau, Bernard","Borot, Sophie","Bourgeon-Ghittori, Muriel","Bourron, Olivier","Boutoille, David","Cazenave-Roblot, France","Chaumeil, Claude","Cosson, Emmanuel","Coudol, Sandrine","Darmon, Patrice","Disse, Emmanuel","Ducet-Boiffard, Amelie","Gaborit, Benedicte","Joubert, Michael","Kerlan, Veronique","Laviolle, Bruno","Marchand, Lucien","Meyer, Laurent","Potier, Louis","Prevost, Gaetan","Riveline, Jean-Pierre","Robert, Rene","Saulnier, Pierre-Jean","Sultan, Ariane","Thebaut, Jean-Francois","Thivolet, Charles","Tramunt, Blandine","Vatier, Camille","Roussel, Ronan","Gautier, Jean-Francois","Gourdy, Pierre","32472191"],"abstract":["AIMS/HYPOTHESIS: Coronavirus disease-2019 (COVID-19) is a life-threatening infection caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) virus. Diabetes has rapidly emerged as a major comorbidity for COVID-19 severity. However, the phenotypic characteristics of diabetes in COVID-19 patients are unknown. METHODS: We conducted a nationwide multicentre observational study in people with diabetes hospitalised for COVID-19 in 53 French centres in the period 10-31 March 2020. The primary outcome combined tracheal intubation for mechanical ventilation and/or death within 7 days of admission. Age- and sex-adjusted multivariable logistic regressions were performed to assess the prognostic value of clinical and biological features with the endpoint. ORs are reported for a 1 SD increase after standardisation. RESULTS: The current analysis focused on 1317 participants: 64.9% men, mean age 69.8 +/- 13.0 years, median BMI 28.4 (25th-75th percentile: 25.0-32.7) kg/m(2); with a predominance of type 2 diabetes (88.5%). Microvascular and macrovascular diabetic complications were found in 46.8% and 40.8% of cases, respectively. The primary outcome was encountered in 29.0% (95% CI 26.6, 31.5) of participants, while 10.6% (9.0, 12.4) died and 18.0% (16.0, 20.2) were discharged on day 7. In univariate analysis, characteristics prior to admission significantly associated with the primary outcome were sex, BMI and previous treatment with renin-angiotensin-aldosterone system (RAAS) blockers, but not age, type of diabetes, HbA1c, diabetic complications or glucose-lowering therapies. In multivariable analyses with covariates prior to admission, only BMI remained positively associated with the primary outcome (OR 1.28 [1.10, 1.47]). On admission, dyspnoea (OR 2.10 [1.31, 3.35]), as well as lymphocyte count (OR 0.67 [0.50, 0.88]), C-reactive protein (OR 1.93 [1.43, 2.59]) and AST (OR 2.23 [1.70, 2.93]) levels were independent predictors of the primary outcome. Finally, age (OR 2.48 [1.74, 3.53]), treated obstructive sleep apnoea (OR 2.80 [1.46, 5.38]), and microvascular (OR 2.14 [1.16, 3.94]) and macrovascular complications (OR 2.54 [1.44, 4.50]) were independently associated with the risk of death on day 7. CONCLUSIONS/INTERPRETATIONS: In people with diabetes hospitalised for COVID-19, BMI, but not long-term glucose control, was positively and independently associated with tracheal intubation and/or death within 7 days. TRIAL REGISTRATION: clinicaltrials.gov NCT04324736."],"journal":"Diabetologia","authors":["Cariou, Bertrand","Hadjadj, Samy","Wargny, Matthieu","Pichelin, Matthieu","Al-Salameh, Abdallah","Allix, Ingrid","Amadou, Coralie","Arnault, Gwenaelle","Baudoux, Florence","Bauduceau, Bernard","Borot, Sophie","Bourgeon-Ghittori, Muriel","Bourron, Olivier","Boutoille, David","Cazenave-Roblot, France","Chaumeil, Claude","Cosson, Emmanuel","Coudol, Sandrine","Darmon, Patrice","Disse, Emmanuel","Ducet-Boiffard, Amelie","Gaborit, Benedicte","Joubert, Michael","Kerlan, Veronique","Laviolle, Bruno","Marchand, Lucien","Meyer, Laurent","Potier, Louis","Prevost, Gaetan","Riveline, Jean-Pierre","Robert, Rene","Saulnier, Pierre-Jean","Sultan, Ariane","Thebaut, Jean-Francois","Thivolet, Charles","Tramunt, Blandine","Vatier, Camille","Roussel, Ronan","Gautier, Jean-Francois","Gourdy, Pierre"],"date":"2020-05-31T11:00:00Z","year":2020,"_id":"32472191","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1007/s00125-020-05180-x","keywords":["bmi","covid-19","death","diabetes","hba1c","hypertension","mechanical ventilation"],"locations":["French"],"countries":["France"],"countries_codes":["FRA|France"],"topics":["Treatment","Diagnosis"],"weight":1,"_version_":1668255193431539714,"score":93.66129},{"pmid":32233013,"title":"Diabetes is a risk factor for the progression and prognosis of COVID-19.","text":["Diabetes is a risk factor for the progression and prognosis of COVID-19.","BACKGOUND: To figure out whether diabetes is a risk factor influencing the progression and prognosis of 2019 novel coronavirus disease (COVID-19). METHODS: A total of 174 consecutive patients confirmed with COVID-19 were studied. Demographic data, medical history, symptoms and signs, laboratory findings, chest computed tomography (CT) as well the treatment measures were collected and analysed. RESULTS: We found that COVID-19 patients without other comorbidities but with diabetes (n = 24) were at higher risk of severe pneumonia, release of tissue injury-related enzymes, excessive uncontrolled inflammation responses and hypercoagulable state associated with dysregulation of glucose metabolism. Furthermore, serum levels of inflammation-related biomarkers such as IL-6, C-reactive protein, serum ferritin and coagulation index, D-dimer, were significantly higher (P < .01) in diabetic patients compared with those without, suggesting that patients with diabetes are more susceptible to an inflammatory storm eventually leading to rapid deterioration of COVID-19. CONCLUSIONS: Our data support the notion that diabetes should be considered as a risk factor for a rapid progression and bad prognosis of COVID-19. More intensive attention should be paid to patients with diabetes, in case of rapid deterioration.","Diabetes Metab Res Rev","Guo, Weina","Li, Mingyue","Dong, Yalan","Zhou, Haifeng","Zhang, Zili","Tian, Chunxia","Qin, Renjie","Wang, Haijun","Shen, Yin","Du, Keye","Zhao, Lei","Fan, Heng","Luo, Shanshan","Hu, Desheng","32233013"],"abstract":["BACKGOUND: To figure out whether diabetes is a risk factor influencing the progression and prognosis of 2019 novel coronavirus disease (COVID-19). METHODS: A total of 174 consecutive patients confirmed with COVID-19 were studied. Demographic data, medical history, symptoms and signs, laboratory findings, chest computed tomography (CT) as well the treatment measures were collected and analysed. RESULTS: We found that COVID-19 patients without other comorbidities but with diabetes (n = 24) were at higher risk of severe pneumonia, release of tissue injury-related enzymes, excessive uncontrolled inflammation responses and hypercoagulable state associated with dysregulation of glucose metabolism. Furthermore, serum levels of inflammation-related biomarkers such as IL-6, C-reactive protein, serum ferritin and coagulation index, D-dimer, were significantly higher (P < .01) in diabetic patients compared with those without, suggesting that patients with diabetes are more susceptible to an inflammatory storm eventually leading to rapid deterioration of COVID-19. CONCLUSIONS: Our data support the notion that diabetes should be considered as a risk factor for a rapid progression and bad prognosis of COVID-19. More intensive attention should be paid to patients with diabetes, in case of rapid deterioration."],"journal":"Diabetes Metab Res Rev","authors":["Guo, Weina","Li, Mingyue","Dong, Yalan","Zhou, Haifeng","Zhang, Zili","Tian, Chunxia","Qin, Renjie","Wang, Haijun","Shen, Yin","Du, Keye","Zhao, Lei","Fan, Heng","Luo, Shanshan","Hu, Desheng"],"date":"2020-04-02T11:00:00Z","year":2020,"_id":"32233013","source":"PubMed","week":"202014|Mar 30 - Apr 05","doi":"10.1002/dmrr.3319","keywords":["covid-19","diabetes","prognosis"],"topics":["Diagnosis"],"weight":1,"_version_":1666138492208414720,"score":89.41897},{"pmid":32479159,"title":"Related molecular mechanisms of COVID-19, hypertension, and diabetes.","text":["Related molecular mechanisms of COVID-19, hypertension, and diabetes.","Am J Physiol Endocrinol Metab","Akkus, Erman","Sahin, Mustafa","32479159"],"journal":"Am J Physiol Endocrinol Metab","authors":["Akkus, Erman","Sahin, Mustafa"],"date":"2020-06-02T11:00:00Z","year":2020,"_id":"32479159","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1152/ajpendo.00164.2020","keywords":["covid-19","diabetes","hypertension"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1668437834921410560,"score":87.31016},{"pmid":32456948,"pmcid":"PMC7165120","title":"Cardiovascular disease potentially contributes to the progression and poor prognosis of COVID-19.","text":["Cardiovascular disease potentially contributes to the progression and poor prognosis of COVID-19.","BACKGROUND AND AIM: A novel coronavirus severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) caused pneumonia, Coronavirus Disease 2019 (COVID-19), broke out in Wuhan, China in December 2019, and spread all over the world. Patients with COVID-19 showed huge differences in the hospital stay, progression, and prognosis. As reported, the comorbidities may play an important role in COVID-19. Here, we aim to address the role of cardiovascular disease (CVD) in the progression and prognosis of COVID-19. METHODS AND RESULTS: Eighty-three confirmed COVID-19 patients were divided into CVD (n = 42) and non-CVD (n = 41) group according to their medical history. Medical records including demographic data, medical history, clinical characteristics, laboratory examinations, chest computed tomography (CT), and treatment measures were collected, analyzed, and compared between the two groups. COVID-19 patients with CVD showed (1) more severe pathological changes in the lungs, (2) elevated injury-related enzymes including alpha-hydroxybutyrate dehydrogenase (HDBH), lactic dehydrogenase (LDH), gamma-glutamyltransferase (GGT), creatine kinase (CK), and alanine aminotransferase (ALT), (3) significantly increased uncontrolled inflammation related markers, such as c-reactive protein (CRP), interleukin (IL)-6, serum ferritin, erythrocyte sedimentation rate (ESR), and serum amyloid A (SAA), (4) serious hypercoagulable status reflected by increased D-dimer and serum fibrinogen (FIB), and (5) higher mortality, compared to COVID-19 patients without CVD. CONCLUSIONS: Our data indicated that CVD is a strong risk factor for rapid progression and bad prognosis of COVID-19. More intensive medical care should be applied to patients with CVD to prevent rapid deterioration of the disease.","Nutr Metab Cardiovasc Dis","Li, Mingyue","Dong, Yalan","Wang, Haijun","Guo, Weina","Zhou, Haifeng","Zhang, Zili","Tian, Chunxia","Du, Keye","Zhu, Rui","Wang, Li","Zhao, Lei","Fan, Heng","Luo, Shanshan","Hu, Desheng","32456948"],"abstract":["BACKGROUND AND AIM: A novel coronavirus severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) caused pneumonia, Coronavirus Disease 2019 (COVID-19), broke out in Wuhan, China in December 2019, and spread all over the world. Patients with COVID-19 showed huge differences in the hospital stay, progression, and prognosis. As reported, the comorbidities may play an important role in COVID-19. Here, we aim to address the role of cardiovascular disease (CVD) in the progression and prognosis of COVID-19. METHODS AND RESULTS: Eighty-three confirmed COVID-19 patients were divided into CVD (n = 42) and non-CVD (n = 41) group according to their medical history. Medical records including demographic data, medical history, clinical characteristics, laboratory examinations, chest computed tomography (CT), and treatment measures were collected, analyzed, and compared between the two groups. COVID-19 patients with CVD showed (1) more severe pathological changes in the lungs, (2) elevated injury-related enzymes including alpha-hydroxybutyrate dehydrogenase (HDBH), lactic dehydrogenase (LDH), gamma-glutamyltransferase (GGT), creatine kinase (CK), and alanine aminotransferase (ALT), (3) significantly increased uncontrolled inflammation related markers, such as c-reactive protein (CRP), interleukin (IL)-6, serum ferritin, erythrocyte sedimentation rate (ESR), and serum amyloid A (SAA), (4) serious hypercoagulable status reflected by increased D-dimer and serum fibrinogen (FIB), and (5) higher mortality, compared to COVID-19 patients without CVD. CONCLUSIONS: Our data indicated that CVD is a strong risk factor for rapid progression and bad prognosis of COVID-19. More intensive medical care should be applied to patients with CVD to prevent rapid deterioration of the disease."],"journal":"Nutr Metab Cardiovasc Dis","authors":["Li, Mingyue","Dong, Yalan","Wang, Haijun","Guo, Weina","Zhou, Haifeng","Zhang, Zili","Tian, Chunxia","Du, Keye","Zhu, Rui","Wang, Li","Zhao, Lei","Fan, Heng","Luo, Shanshan","Hu, Desheng"],"date":"2020-05-28T11:00:00Z","year":2020,"_id":"32456948","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1016/j.numecd.2020.04.013","keywords":["covid-19","cardiovascular disease","prognosis"],"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment","Diagnosis"],"weight":1,"_version_":1668141322616176640,"score":84.18456}]}